Cartesian Therapeutics Inc
RNAC
Detailliertes Diagramm anzeigen
7.550USD
-0.120-1.56%
Handelsschluss 11/06, 16:00（ET）Kurse um 15 Minuten verzögert
196.30MMarktkapitalisierung
VerlustKGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
-1.56%
5 Tage
-6.91%
1 Monat
-24.50%
6 Monate
-28.57%
Seit Jahresbeginn
-57.84%
1 Jahr
-63.81%
Detailliertes Diagramm anzeigen
TradingKey Aktienbewertung von Cartesian Therapeutics Inc
Währung: USD Aktualisiert: 2025-11-06Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ stabil. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer sehr schwachen Marktentwicklung zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Cartesian Therapeutics Inc Bewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
9
Analysten
Kaufen
Aktuelles Rating
36.429
Kursziel
+374.95%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Cartesian Therapeutics Inc Highlights
HöhepunkteRisiko
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
performance_growth_period
performance_growth_period_desc%!(EXTRA string=38.91M)
valuation_underestimated
valuation_underestimated_desc%!(EXTRA string=PE, string=-11.30)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=6.62M, string=13.15%)
institutional_hold%!(EXTRA string=Scott Black)
institutional_hold_desc%!(EXTRA string=Scott Black, string=22.03K)
Cartesian Therapeutics Inc Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Cartesian Therapeutics Inc Informationen
Cartesian Therapeutics, Inc. is a clinical-stage company. The Company is engaged in developing messenger ribonucleic acids (mRNA) cell therapies for the treatment of autoimmune diseases. It is leveraging its proprietary technology and manufacturing platform, RNA Armory, to develop mRNA cell therapies for autoimmune diseases. Its lead asset e, Descartes-08, is an autologous mRNA chimeric antigen receptor T-cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), that the Company is developing for the treatment of autoimmune diseases. Descartes-08 is in Phase II clinical development. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.
BörsenkürzelRNAC
UnternehmenCartesian Therapeutics Inc
CEODr. Carsten Brunn, Ph.D.
Websitehttps://www.cartesiantherapeutics.com/
Verwandte Finanzinstrumente
+1.26%
+0.52%
+1.05%
+3.23%
+0.85%
+1.65%
-1.33%
-4.02%
+0.67%
+0.98%
+1.00%
+1.70%
-0.18%
+0.34%
+0.88%
+1.07%
0.00%
+0.42%
+1.36%
-0.77%Beliebte Symbole
